Compare NNBR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | LUNG |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 72.2M |
| IPO Year | 1996 | 2020 |
| Metric | NNBR | LUNG |
|---|---|---|
| Price | $1.24 | $1.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $5.38 |
| AVG Volume (30 Days) | 212.4K | ★ 639.0K |
| Earning Date | 06-12-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.60 | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $770,657,000.00 | $90,497,000.00 |
| Revenue This Year | $8.27 | $6.20 |
| Revenue Next Year | $5.38 | $21.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $1.10 | $1.31 |
| 52 Week High | $2.67 | $8.10 |
| Indicator | NNBR | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 47.75 |
| Support Level | $1.20 | $1.44 |
| Resistance Level | $1.43 | $1.69 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 6.17 | 27.33 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.